FDA ta ba da izinin sabon kwayar COVID-19, daga Merck

A yau, Amurka Hukumar Abinci da Magunguna (FDA) An ba da izinin yin amfani da gaggawa (EUA) don Merck's molnupiravir don kula da cutar sankara-zuwa-matsakaici (COVID-19) a cikin manya tare da ingantaccen sakamako na gwajin hoto na SARS-CoV-2 kai tsaye, kuma waɗanda ke cikin haɗarin ci gaba. zuwa COVID-19 mai tsanani, gami da asibiti ko mutuwa, kuma ga wanda madadin zaɓuɓɓukan jiyya na COVID-19 waɗanda FDA ta ba su izini ko dacewa a asibiti. molnupiravir yana samuwa ta hanyar takardar sayan magani kawai kuma yakamata a fara farawa da wuri-wuri bayan gano cutar ta COVID-19 kuma cikin kwanaki biyar na bayyanar cututtuka.

Ba a ba da izinin Molnupiravir don amfani da marasa lafiya da ke ƙasa da shekaru 18 ba saboda molnupiravir na iya shafar haɓakar ƙashi da guringuntsi. Ba a ba da izini ba don rigakafin farko ko bayyanar bayan bayyanar COVID-19 ko don fara jiyya a cikin marasa lafiya da ke asibiti saboda COVID-19 saboda ba a lura da fa'idar jiyya a cikin mutane ba lokacin da aka fara jiyya bayan an kwantar da shi a asibiti saboda COVID- 19.  

“Izinin yau yana ba da ƙarin zaɓin magani a kan cutar ta COVID-19 ta hanyar kwaya da za a iya sha da baki. molnupiravir yana iyakance ga yanayin da wasu FDAPatrizia Cavazzoni, MD, darektan asibitin ya ce - magungunan da aka ba da izini don COVID-19 ba su da isa ko kuma ba su dace da asibiti ba kuma za su zama zaɓi mai amfani ga wasu marasa lafiya tare da COVID-19 a cikin haɗarin asibiti ko mutuwa, "in ji Patrizia Cavazzoni, MD, darektan cibiyar. FDA's Center for Drug Evaluation and Research. "Yayin da sabbin bambance-bambancen kwayar cutar ke ci gaba da fitowa, yana da matukar muhimmanci a fadada makaman kasar na COVID-19 ta hanyar amfani da izinin amfani da gaggawa, yayin da ake ci gaba da samar da karin bayanai kan amincinsu da ingancinsu."

Molnupiravir ba madadin alluran rigakafi ba ne a cikin daidaikun waɗanda aka ba da shawarar rigakafin COVID-19 da ƙarin adadin kuzari. The FDA ya amince da rigakafin guda ɗaya kuma ya ba da izini ga wasu don hana COVID-19 da sakamako mai tsanani na asibiti da ke da alaƙa da kamuwa da cutar COVID-19, gami da asibiti da mutuwa. FDA ta bukaci jama'a da su yi allurar rigakafi kuma su sami abin ƙarfafawa idan sun cancanta. Koyi ƙarin koyo game da yarda da FDA-ko - izini na rigakafin COVID-19.

molnupiravir magani ne wanda ke aiki ta hanyar shigar da kurakurai a cikin lambar kwayoyin halittar kwayar cutar SARS-CoV-2, wanda ke hana kwayar cutar sake yin kwafi. Ana yin amfani da Molnupiravir a matsayin capsules na milligram 200 guda hudu da ake sha da baki kowane sa'o'i 12 na tsawon kwanaki biyar, jimlar capsules 40. molnupiravir ba a ba da izini don amfani fiye da kwanaki biyar a jere ba.